Paolo Tarantino: Opportunities to improve outcomes for early recurrent TNBC

Paolo Tarantino shared a post on X:         . 

“Early recurrent TNBC (Triple-Negative Breast Cancer) is one of the toughest challenges in breast oncology.

What is its biology, how to treat it?

In this editorial, Sara Tolaney and I discuss the results of IMp132, highlighting opportunities to improve outcomes for this hard-to-treat entity.”

Proceed to the article.
Source: Paolo Tarantino/X

Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.